-
Cancer Management and Research
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
Review
(2380) Views (593) Full article downloads
Author: Jochen H Lorch
Published Date November 2009
Volume 2009:1 Pages 151 - 154
DOI: http://dx.doi.org/10.2147/CMAR.S5134
Jochen H Lorch
Dana Farber Cancer institute, Boston, MA, USA
Abstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor receptor has become an established treatment strategy in SCCHN both in the up-front treatment and in the recurrent and metastatic setting. This review summarizes the most important developments of the recent past and provides an overview of newer developments.
Keywords: squamous cell cancer, head, neck, epidermal growth factor receptor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma
